LEADER 05297nam 2201705z- 450 001 9910557385403321 005 20210501 035 $a(CKB)5400000000042045 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68583 035 $a(oapen)doab68583 035 $a(EXLCZ)995400000000042045 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvances in Multiple Sclerosis Research-Series I 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (334 p.) 311 08$a3-03943-947-2 311 08$a3-03943-948-0 330 $aDesigning immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials. 606 $aMedicine$2bicssc 610 $aadult-onset 610 $aagonist peptide 610 $aalemtuzumab 610 $aaltered peptide ligands 610 $aantibodies against GluR3 peptide 610 $aantibody detection 610 $aantigen-specific immunotherapies 610 $aantigen-specific immunotherapy 610 $aastrocytes 610 $aautoimmune diseases 610 $aautoimmune encephalitis 610 $aautoimmunity 610 $aB cell receptor 610 $abiomarker 610 $abupropion 610 $acarriers 610 $acellular immunity 610 $acentral nervous system 610 $acerebral blood flow 610 $achloroquine 610 $aclinical outcome 610 $aclinical outcomes 610 $aclinical phenotype 610 $acognitive impairment 610 $aconformational analysis 610 $aconjugation 610 $acranial nerve-VI palsy 610 $acraniopharyngioma 610 $adelivery methods 610 $adendritic cells 610 $adiagnosis 610 $adiagnostic markers 610 $adisease-modifying treatments 610 $adrug delivery nanosystems 610 $aEAE 610 $aearly-onset 610 $aELISA 610 $aexperimental autoimmune encephalomyelitis 610 $afampridine 610 $afractionated stereotactic radiation treatments 610 $afree light chains 610 $aGraphite/SiO2 electrode 610 $agut microbiome 610 $agut-brain axis 610 $aHPLC 610 $aHuman Leucocyte Antigens 610 $aimmune modulation 610 $aimmune thrombocytopenic purpura 610 $aimmunogenetics 610 $aimmunoglobulins 610 $aimmunomodulation 610 $aimmunotherapeutics 610 $aimmunotherapy 610 $ainflammation 610 $aintracortical facilitation 610 $akappa 610 $alipids 610 $amajor depression 610 $amannan 610 $aMBP83-99 peptide 610 $amemory T cells 610 $ametagenomics 610 $amicroglia 610 $aMOG35-55 610 $amolecular dynamic 610 $amonoclonal antibodies 610 $aMS 610 $aMS drugs 610 $amultiple sclerosis 610 $aMultiple Sclerosis 610 $amultivalency 610 $amyelin basic protei 610 $amyelin oligodendrocyte glycoprotein 610 $amyelin peptides 610 $aN-glucosylated peptide epitopes 610 $ananoparticles 610 $ananotechnology 610 $aneurodegeneration 610 $aneuroimaging 610 $aneuropsychological assessment 610 $aNMR spectroscopy 610 $aNOE-constraints 610 $aoligodendrocytes 610 $aoxidative 610 $apeptide 610 $apeptides 610 $aplasma exchange 610 $apolymers 610 $apositron emission tomography 610 $aprobiotics 610 $aproteolipid protein 610 $aS-adenosylmethionine 610 $asample size 610 $ashort intracortical inhibition 610 $asphenoid sinusitis 610 $aST285 610 $aStreptococcus thermophilus 610 $aT cell receptor 610 $atDCS 610 $atetraspanins 610 $atherapeutics 610 $atolerance 610 $atolerance induction 610 $atolerogenic vaccines 610 $atrimolecular complex 610 $aTSPAN32 610 $avaccine 610 $avaccines 610 $avitamin D3 610 $avoltammetry 610 $awalking disability 610 $ayoga 615 7$aMedicine 700 $aMatsoukas$b John$4edt$01309053 702 $aApostolopoulos$b Vasso$4edt 702 $aMatsoukas$b John$4oth 702 $aApostolopoulos$b Vasso$4oth 906 $aBOOK 912 $a9910557385403321 996 $aAdvances in Multiple Sclerosis Research-Series I$93029272 997 $aUNINA LEADER 02169nam 2200505z- 450 001 9910557603303321 005 20211118 035 $a(CKB)5400000000045370 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/74338 035 $a(oapen)doab74338 035 $a(EXLCZ)995400000000045370 100 $a20202111d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAtypical Functions of Leukocyte Chemoattractant Receptors 210 $cFrontiers Media SA$d2020 215 $a1 online resource (95 p.) 311 08$a2-88966-205-5 330 $aThis eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact 606 $aImmunology$2bicssc 606 $aMedicine and Nursing$2bicssc 610 $aarrestin 610 $aatypical chemokine receptor 610 $achemokine 610 $achemotaxis 610 $aG protein-coupled receptor 610 $aGPCR 610 $asignaling 615 7$aImmunology 615 7$aMedicine and Nursing 700 $aLuis Rodríguez-Fernández$b José$4edt$01292436 702 $aMellado$b Mario$4edt 702 $aThelen$b Marcus$4edt 702 $aMurphy$b Philip M$4edt 702 $aLuis Rodríguez-Fernández$b José$4oth 702 $aMellado$b Mario$4oth 702 $aThelen$b Marcus$4oth 702 $aMurphy$b Philip M$4oth 906 $aBOOK 912 $a9910557603303321 996 $aAtypical Functions of Leukocyte Chemoattractant Receptors$93022306 997 $aUNINA